Amer Assal, MD

Call
Website

Advertisement

Photos

520 E 70th St Fl 3
New York, NY 10021
Amer Assal MD is a board certified medical oncologist and hematologist who specializes in the use of autologous and allogeneic bone marrow stem cell transplantation for the treatment of multiple myeloma, leukemia, lymphoma, myelodysplastic syndromes and other bone marrow disorders. Dr. Assal completed his medical education and internal medicine training at NYU School of Medicine. He was also a hospitalist in the department of medicine at Memorial Sloan Kettering Cancer Center caring for patients with a variety of cancer diagnoses, including stem cell transplant patients. Dr. Assal completed a fellowship in hematology and medical oncology at Albert Einstein College of Medicine where he also served as chief fellow. He finally completed a fellowship in blood and marrow stem cell transplantation at Memorial Sloan Kettering Cancer Center. His research interests center around improving outcomes of stem cell transplantation and the diseases it is used to treat. He has a particular interest in immunotherapy and studying ways to harness the immune system to attack tumor cells, while at the same time decreasing the risk of graft versus host disease. He is also interested in studying therapeutic interventions to prevent and treat relapse of disease after stem cell transplantation. He has presented his research at several national conferences and was awarded an American Society of Hematology Abstract Achievement award for his research.
Owner verified
See a problem?

You might also like

Babak Navi, M.D., M.S.
Internal medicine practitioners, Psychiatrists and psychoanalysts

Babak Navi, M.D., M.S.

Babak Navi, MD, MSBabak Navi, M.D., M.S. received his medical degree from New York University, where he graduated with honors. He completed a residency in neurology at Weill Cornell Medical Center and served as the Chief Resident in his final year. He completed a fellowship in vascular neurology at the University of California, San Francisco, where he also became certified in comprehensive neurosonology. In 2011, Dr. Navi joined the neurology faculty at Weill Cornell Medical College. Here, he received a Masters of Science in Research from the Cornell Graduate School of Medical Sciences. Dr. Navi is currently an Associate Professor of Neurology and Neuroscience, the Vice Chair for Neurology Hospital Services, and the Division Chief of Stroke and Hospital Neurology. He also serves as the Medical Director of the Weill Cornell Stroke Center and Acting Director of the NewYork-Presbyterian Hospital Mobile Stroke Unit Program.Dr. Navi is an expert on the relationship between cancer and stroke. He has published numerous studies on this topic and led the first randomized trial to compare different blood thinning strategies for patients with cancer and stroke. Dr. Navi has also conducted research studies on stroke of undetermined cause, stroke during pregnancy and other prothrombotic states, the safety and efficacy of mobile stroke units, and physicians’ ability to prognosticate in severe brain injury. His work has been published in leading medical journals, including the NEJM, JAMA, JACC, Neurology, Annals of Neurology, JAMA Neurology, Stroke, and Critical Care Medicine. Dr. Navi has been awarded several research grants during his career, including from the NIH, PCORI, and foundations. He has considerable experience in conducting clinical trials and served as the Cornell Site Principal Investigator for the landmark POINT and BEST-MSU trials. Dr. Navi is an Associate Editor for the journal Neurohospitalist and an editorial board member for JAMA Neurology. He received the Young Heart Award by the American Heart Association New York Chapter in 2017. Select Publications1. Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70:926-938. 2. Navi BB, Reiner AS, Kamel H, Iadecola C, Elkind MSV, Panageas KS, DeAngelis LM. Association between incident cancer and subsequent stroke. Ann Neurol. 2015;77:291-300. 3. Navi BB, Marshall RS, Bobrow D, Singer S, Stone JB, DeSancho MT, DeAngelis LM. Enoxaparin vs. aspirin in patients with cancer and ischemic stroke: the TEACH pilot randomized clinical trial. JAMA Neurol. 2018;75:379-381. 4. Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MSV. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med. 2014;370:1307-1315.5. Navi BB, Singer S, Merkler AE, Cheng NT, Stone JB, Kamel H, Iadecola C, Elkind MS, DeAngelis LM. Recurrent thromboembolic events after ischemic stroke in patients with cancer. Neurology. 2014;83:26-33.
United StatesNew YorkNew YorkAmer Assal, MD

Yext

Advertisement